Grantham, Mayo, Van Otterloo & Co (GMO)
RNA

Grantham, Mayo, Van Otterloo & Co (GMO)’s Atrium Therapeutics RNA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,444
Closed -$206K – 737
2026
Q1 		$206K Buy
+15,444
New +$217K ﹤0.01% 613

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RNA Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 15,444 shares — an estimated $206K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $206K in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 15,444 Atrium Therapeutics shares in Q2 2026, an estimated $206K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Atrium Therapeutics position peaked at $206K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.